Stay updated on Durvalumab & Olaparib in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page.

Latest updates to the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page
- Check7 days agoChange DetectedResults have been posted for NCT04269200, with enrollment updated to 805 and 202 locations (including Erlangen, Germany). The page now lists a broad set of outcome measures (PFS, OS, PFS2, ORR, DoR, TFST, TSST, TDT, PK, ADA, and HRQoL) along with their assessment schedules.SummaryDifference1%

- Check14 days agoChange DetectedLocations for many US states and Canadian provinces were added and removed, and a Revision: v3.3.3 appears, signaling an update to the listing of study sites.SummaryDifference1%

- Check22 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe page now shows Revision: v3.3.2, replacing Revision: v3.3.1.SummaryDifference0.0%

- Check43 days agoChange DetectedAdded a note that PubMed-derived publications are automatically filled for the study page and may not be about the study, and updated the revision to v3.3.1; removed the previous PubMed note and Revision: v3.2.0.SummaryDifference0.0%

- Check50 days agoChange DetectedDeleted the generic government operating status notice from the page, which does not affect the study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedThe new screenshot shows the same study details and locations with only minor formatting or rendering differences. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Durvalumab & Olaparib in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Olaparib in Endometrial Cancer Clinical Trial page.